Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables,… Read more
Merck KGaA (MRK) - Net Assets
Latest net assets as of September 2025: €29.00 Billion EUR
Based on the latest financial reports, Merck KGaA (MRK) has net assets worth €29.00 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€50.93 Billion) and total liabilities (€21.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €29.00 Billion |
| % of Total Assets | 56.94% |
| Annual Growth Rate | 12.96% |
| 5-Year Change | 76.22% |
| 10-Year Change | 133.27% |
| Growth Volatility | 26.07 |
Merck KGaA - Net Assets Trend (2002–2024)
This chart illustrates how Merck KGaA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Merck KGaA (2002–2024)
The table below shows the annual net assets of Merck KGaA from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €29.99 Billion | +12.08% |
| 2023-12-31 | €26.75 Billion | +2.88% |
| 2022-12-31 | €26.00 Billion | +21.43% |
| 2021-12-31 | €21.42 Billion | +25.85% |
| 2020-12-31 | €17.02 Billion | -5.00% |
| 2019-12-31 | €17.91 Billion | +3.95% |
| 2018-12-31 | €17.23 Billion | +22.52% |
| 2017-12-31 | €14.07 Billion | +0.11% |
| 2016-12-31 | €14.05 Billion | +9.29% |
| 2015-12-31 | €12.86 Billion | +8.93% |
| 2014-12-31 | €11.80 Billion | +6.61% |
| 2013-12-31 | €11.07 Billion | +6.28% |
| 2012-12-31 | €10.41 Billion | -0.75% |
| 2011-12-31 | €10.49 Billion | +1.17% |
| 2010-12-31 | €10.37 Billion | +9.02% |
| 2009-12-31 | €9.51 Billion | -1.11% |
| 2008-12-31 | €9.62 Billion | +10.74% |
| 2007-12-31 | €8.69 Billion | +128.18% |
| 2006-12-31 | €3.81 Billion | +14.37% |
| 2005-12-31 | €3.33 Billion | +15.00% |
| 2004-12-31 | €2.89 Billion | +22.52% |
| 2003-12-31 | €2.36 Billion | +15.06% |
| 2002-12-31 | €2.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Merck KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2208600000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €22.09 Billion | 73.84% |
| Common Stock | €565.00 Million | 1.89% |
| Other Comprehensive Income | €3.11 Billion | 10.41% |
| Other Components | €4.15 Billion | 13.86% |
| Total Equity | €29.91 Billion | 100.00% |
Merck KGaA Competitors by Market Cap
The table below lists competitors of Merck KGaA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pentair PLC
NYSE:PNR
|
$14.39 Billion |
|
Terna Rete Elettrica Nazionale SpA
LSE:0LBM
|
$14.40 Billion |
|
Genuine Parts Co
NYSE:GPC
|
$14.41 Billion |
|
Bureau Veritas SA
PINK:BVVBY
|
$14.42 Billion |
|
Viking Holdings Ltd
NYSE:VIK
|
$14.37 Billion |
|
Teck Resources Limited
PINK:TCKRF
|
$14.35 Billion |
|
CLP Holdings Ltd
PINK:CLPHY
|
$14.34 Billion |
|
Wal Mart de Mexico SAB de CV
PINK:WMMVF
|
$14.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Merck KGaA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,680,000,000 to 29,912,000,000, a change of 3,232,000,000 (12.1%).
- Net income of 2,777,000,000 contributed positively to equity growth.
- Dividend payments of 284,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,447,000,000.
- Other factors decreased equity by 708,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.78 Billion | +9.28% |
| Dividends Paid | €284.00 Million | -0.95% |
| Other Comprehensive Income | €1.45 Billion | +4.84% |
| Other Changes | €-708.00 Million | -2.37% |
| Total Change | €- | 12.11% |
Book Value vs Market Value Analysis
This analysis compares Merck KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.78x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €5.76 | €108.20 | x |
| 2003-12-31 | €6.36 | €108.20 | x |
| 2004-12-31 | €7.41 | €108.20 | x |
| 2005-12-31 | €8.32 | €108.20 | x |
| 2006-12-31 | €9.67 | €108.20 | x |
| 2007-12-31 | €19.98 | €108.20 | x |
| 2008-12-31 | €21.86 | €108.20 | x |
| 2009-12-31 | €21.76 | €108.20 | x |
| 2010-12-31 | €23.76 | €108.20 | x |
| 2011-12-31 | €24.03 | €108.20 | x |
| 2012-12-31 | €23.86 | €108.20 | x |
| 2013-12-31 | €25.39 | €108.20 | x |
| 2014-12-31 | €26.99 | €108.20 | x |
| 2015-12-31 | €29.36 | €108.20 | x |
| 2016-12-31 | €32.20 | €108.20 | x |
| 2017-12-31 | €32.20 | €108.20 | x |
| 2018-12-31 | €39.56 | €108.20 | x |
| 2019-12-31 | €41.09 | €108.20 | x |
| 2020-12-31 | €38.98 | €108.20 | x |
| 2021-12-31 | €49.08 | €108.20 | x |
| 2022-12-31 | €59.63 | €108.20 | x |
| 2023-12-31 | €61.36 | €108.20 | x |
| 2024-12-31 | €68.80 | €108.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Merck KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.28%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.13%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.72x
- Recent ROE (9.28%) is below the historical average (13.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 10.69% | 2.91% | 0.99x | 3.73x | €13.88 Million |
| 2003 | 9.33% | 3.02% | 1.03x | 2.99x | €-15.66 Million |
| 2004 | 23.55% | 12.58% | 0.93x | 2.01x | €386.61 Million |
| 2005 | 20.53% | 11.46% | 0.81x | 2.22x | €345.03 Million |
| 2006 | 26.68% | 16.00% | 0.77x | 2.16x | €625.97 Million |
| 2007 | 40.81% | 49.88% | 0.47x | 1.73x | €2.66 Billion |
| 2008 | 3.99% | 5.02% | 0.48x | 1.65x | €-571.44 Million |
| 2009 | 3.98% | 4.86% | 0.46x | 1.77x | €-569.31 Million |
| 2010 | 6.21% | 6.90% | 0.41x | 2.17x | €-391.48 Million |
| 2011 | 6.02% | 6.12% | 0.46x | 2.12x | €-415.71 Million |
| 2012 | 5.47% | 5.07% | 0.52x | 2.09x | €-469.44 Million |
| 2013 | 10.91% | 10.84% | 0.53x | 1.89x | €100.20 Million |
| 2014 | 9.86% | 10.06% | 0.44x | 2.22x | €-16.86 Million |
| 2015 | 8.72% | 8.68% | 0.34x | 2.97x | €-163.95 Million |
| 2016 | 11.64% | 10.84% | 0.39x | 2.73x | €230.10 Million |
| 2017 | 18.57% | 16.96% | 0.43x | 2.54x | €1.20 Billion |
| 2018 | 19.62% | 22.74% | 0.40x | 2.14x | €1.65 Billion |
| 2019 | 7.39% | 8.17% | 0.37x | 2.45x | €-466.50 Million |
| 2020 | 11.73% | 11.33% | 0.42x | 2.47x | €292.40 Million |
| 2021 | 14.32% | 15.52% | 0.43x | 2.13x | €921.20 Million |
| 2022 | 12.83% | 14.96% | 0.46x | 1.87x | €733.30 Million |
| 2023 | 10.58% | 13.45% | 0.43x | 1.82x | €156.00 Million |
| 2024 | 9.28% | 13.13% | 0.41x | 1.72x | €-214.20 Million |
Industry Comparison
This section compares Merck KGaA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Merck KGaA (MRK) | €29.00 Billion | 10.69% | 0.76x | $14.39 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $249.40K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.45K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $936.86 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $60.78 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.80 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.87 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |